SCLC

84P - Patterns of care for patients with small cell lung cancer: A survey of German radiation oncology institutions on recommendations for prophylactic cranial irradiation

Authors
  • Chukwuka Eze (DE)
  • Olarn Roengvoraphoj (DE)
  • Maurice Dantes (DE)
  • Reem Abdo (DE)
  • Nina-Sophie Schmidt-Hegemann (DE)
  • Claus Belka (DE)
  • Farkhad Manapov (DE)
Presenter
  • Chukwuka Eze (DE)

Abstract

Background

Prophylactic cranial irradiation in SCLC was first proposed in 1973 and is recommended for patients demonstrating good response to initial therapy. The general pattern of care amongst radiation oncologists in Germany has not been previously evaluated. We conceptualized and conducted this survey to assess patterns of care.

Methods

We surveyed radiation oncology institutions in Germany via an online questionnaire sent by e-mail to member institutions of the German Society for Radiation Oncology (DEGRO e.V.). The questions were based on respondent and treatment characteristics with emphasis on prophylactic cranial irradiation in limited- and extensive-stage SCLC.

Results

We received a total of 95 responses (29% response rate). Of which 64 were completed and returned and hence eligible for evaluation. Sixty-one percent of respondents were between the ages of 50–59, 88% with over 15 years of experience in the management of lung malignancies. Sixty-seven percent of the institutions stage their patients initially with 18F-FDG-PET/CT. Of the 64 responses, 97% recommended delivery of PCI in therapy responders with LS-SCLC compared to 67% with ES-SCLC. Interestingly, a quarter of respondents offered hippocampal-avoidance PCI with only 38% following their patients with serial brain imaging following PCI. Neuropsychological testing was generally not routinely performed.

Conclusions

German radiation oncology institutions showed interesting variations in certain aspects yet in general congruence in SCLC management and PCI delivery in accordance with the updated national and international guidelines. Future randomized clinical trials will further reduce discrepancies regarding delivery of PCI especially in ES-SCLC.

Legal entity responsible for the study

University Hospital, LMU Munich

Funding

Has not received any funding

Disclosure

All authors have declared no conflicts of interest.

Collapse

Previous ePoster
189P - Are pretreatment neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and advanced lung cancer inflamation index (ALI) levels useful in predicting the outcomes of patients with advanced non-small cell lung cancer?

Next ePosters
86P - Prophylactic cranial irradiation in SCLC: A survey of German radiation oncology institutions on recommendations for brain imaging
114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally advanced node-positive non-small cell lung cancer patients with very limited lung function
117P - Feasibility of moderate hypofractionated image-guided thoracic irradiation for locally advanced node-positive non-small cell lung cancer patients with very limited lung function
200PD - High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center
102P - Stereotactic lung radiotherapy for early-stage NSCLC: An institution's experience
144PD - Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors
150P - Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
83P - Radiotherapy improves the survival of patients with extensive disease small cell lung cancer: A propensity matched analysis of surveillance, epidemiology and end results database
196TiP - CheckMate 384: A phase 3b/4 dose-frequency optimization trial of nivolumab in advanced or metastatic NSCLC
59P - Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): An exploratory sub-analysis of the LUX-Lung 8 trial